Advertisement

Topics

CheckMate 214: nivolumab ipilimumab vs sunitinib for advanced or metastatic renal cell carcinoma

04:32 EDT 10 Sep 2017 | ecancermedicalscience

Dr Escudier presents in a press conference at the ESMO 2017 Congress data from the CheckMate 214 trial looking into the efficacy and safety of nivolumab ipilimumab versus sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma,...

Original Article: CheckMate 214: nivolumab ipilimumab vs sunitinib for advanced or metastatic renal cell carcinoma

NEXT ARTICLE

More From BioPortfolio on "CheckMate 214: nivolumab ipilimumab vs sunitinib for advanced or metastatic renal cell carcinoma"

Quick Search
Advertisement
 

Relevant Topics

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...